
price data provid thomson reuter
number may add due round
find antibodi develop
report earn present ph studi result
bispecif antibodi patient b-cell malign
upcom american societi hematolog meet decemb
expect look efficaci safeti toler compani
advanc two bispecif program
ph dose escal studi
relapsed/refractori acut myeloid leukemia aml patient slate start
ph dose escal data patient
neuroendocrin tumor gastrointestin stromal tumor gist expect
also three tumor microenviron tme -activ bispecif
antibodi program current enrol patient ph dose escal studi
intend address patient advanc solid tumor
monotherapi combo
pembrolizumab initi data could
read pipelin news engin
fc fusion protein advanc collabor genentech
could submit ind year end detail around
collabor genentech address previous see note apart
up-front payment potenti mileston payment collabor
genentech retain option co-promot given candid us
also partnership morphosi mor nc develop tafasitamab
monoclon antibodi intend treat cell malign
expect submit bla year end addit data morphosi
partner program ultomiri alexion op laura chico
alreadi approv treat paroxysm nocturn hemoglobinuria
recent approv octob atyp hemolyt urem syndrom expect
royalti ultomiri tafasitamab contribut grow portion
valuat futur
septemb cash cash equival market
secur project finish year
suffici runway maintain oper beyond
recogn revenu third quarter primarili
mileston collabor mileston payment
receiv novarti nv nc respect
revenu quarter also account receiv royalti stream
ultomiri sale research develop expens third quarter
gener administr expens
period net loss report per share ahead
consensu estim
continu page
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
develop number antibodi therapeut incorpor proprietari engin technolog
includ enter ph diseas number bispecif antibodi program
earlier stage develop also number partner asset includ fc-engin
antibodi partner morphosi ph dlbcl alexion-partn ultomiri recent
approv pnh overal believ market undervalu strength xncr pipelin platform
valid recent collabor roch therapeut astella
bispecif antibodi view number key competit advantag compet antibodi
clinic regulatori setback
pipelin inabl
achiev premium price high
reliabl royalti stream
partner program
continu progress bispecif
new success partner
provid addit valu
dec initi ph data
mor bla submiss tafasitamab
submit ind genentech collab
initi ph data
sum-of-part multipl ww sale
plu multipl royalti
ultomiri
steadi clinic progress pipelin candid
xncr
engin antibodi technolog potenti
applic varieti indic
clinical-stag biopharmaceut compani
focus discov develop engin
monoclon antibodi treat sever
threaten diseas unmet medic need
creat bluematrix
reiter rate outperform lower pt sum-of-
part valuat deriv multipl us/ ex-u sales/royalti
r/r aml discount back annual multipl ww royalti
allerg asthma discount back annual multipl us/ex-u
sale discount back multipl
ww royalti mor-partn tafasitamab rr/ dlbcl discount back plu
multipl ww street royalti alxn-partn ultomiri pnh discount back
annual chang pt reflect decis obexelimab valuat given
recent lack clariti develop timelin strateg repriorit
target oncolog focu compani previous valu multipl us/ex-u
sales/royalti obexelimab annual discount rate assum
us co-promote/ex-u royalti licens agreement identifi partner progress
program see potenti upsid valuat sum-of-
part valuat summari key assumpt
mor-partn product expens oper incom interest incom non-op incom incom incom incom ep share dilut share thousand except per share data valuat
sum-of-part multipl ww sale plu multipl royalti
ultomiri discount back
risk attain price rate
risk includ failur clinic failur achiev regulatori approv failur reach sale expect
lower expect royalti payment partner program
david nierengarten jeffrey la rosa matthew barcu certifi view express report accur reflect
person opinion directli indirectli receiv compens payment connect
specif recommend view contain report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
novemb
novemb
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
